Form 4: Applied Therapeutics Director Jay S. Skyler Granted 200,000 Stock Options

Applied Therapeutics, Inc. (APLT) Director Jay S. Skyler was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Summary

• Jay S. Skyler, a Director of Applied Therapeutics, Inc. (APLT), was granted 200,000 stock options on June 9, 2025.
• The stock options have an exercise price of $0.395 per share.
• These options will vest in 36 equal monthly installments from the grant date, contingent upon Mr. Skyler's continuous service.
• Each option represents the right to buy one share of Applied Therapeutics Common Stock.
• The options have an expiration date of June 9, 2035.
• Following this transaction, Mr. Skyler beneficially owns 200,000 derivative securities (stock options) directly.
• A Limited Power of Attorney was granted by Jay S. Skyler to Les Funtleyder and Catherine Thorpe to facilitate the filing of SEC Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder interests, though it is a routine compensation event rather than a significant operational or financial announcement that would drastically alter the company's outlook.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Applied Therapeutics.
• The options provide a long-term incentive for the director to remain engaged and contribute to the company's success, given the 36-month vesting schedule.

Negatives

• The options do not represent immediate cash compensation and their value is contingent on the future stock price exceeding the exercise price.
• The vesting schedule requires continuous service, meaning the options could be forfeited if the director's service terminates before full vesting.

Risks

• The value of the stock options is subject to the volatility of Applied Therapeutics' common stock price; if the stock price does not rise above the exercise price of $0.395, the options may expire worthless.
• The vesting of the options is conditional on the reporting person's continuous service, posing a risk of forfeiture if service is discontinued.

Future Outlook

The grant of stock options with a multi-year vesting schedule indicates a long-term incentive for the director, aligning their future efforts with the company's sustained growth and performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. This method is widely used to attract and retain talent, and to align the interests of leadership with those of shareholders by tying compensation to the company's stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to align leadership incentives with shareholder value creation.
• The 36-month vesting schedule is typical for long-term incentive plans, comparable to similar grants observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, though the specific number of options and exercise price would vary based on company size, stage of development, and compensation philosophy.

Corporate Governance

Related Party Transactions

• The grant of 200,000 stock options to Jay S. Skyler, a Director of Applied Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying a portion of his compensation to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The stock options will vest in 36 equal monthly installments, subject to the director's continuous service.
• The director may choose to exercise the vested options at any time before their expiration date of June 9, 2035, provided the stock price is favorable.

Key Dates

Recommendation

Keywords

Applied Therapeutics, APLT, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Jay S. Skyler, Beneficial Ownership